Completed PHASE1 INTERVENTIONAL 6-arm NCT05840952

A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558

Sponsor: Aligos Therapeutics

Conditions COVID-19

Interventions ALG-097558 ALG-097558 in solution formulation ALG-097558 in tablet formulation Carbamazepine Itraconazole Midazolam Placebo

Updated 7 times since 2023 Last updated: Apr 4, 2025 Started: Jul 4, 2023 Primary completion: Apr 29, 2024 Completion: Apr 29, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates COVID-19 and is currently completed. Aligos Therapeutics leads this study, which shows 7 recorded versions since 2023 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

May 2025 — Present [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Oct 2024 — May 2025 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Jul 2024 [monthly]

Recruiting PHASE1

▶ Show 2 earlier versions

Dec 2023 — Feb 2024 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Jun 2023 — Dec 2023 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aligos Therapeutics

Data source: Aligos Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom